Our aim was to determine whether referral patterns and rates of vertebroplasties at the Mayo Clinic have changed after the publication of the INVEST and the Australian Trial. In August of 2009, we performed a retrospective review of patients undergoing vertebroplasties and those patients who were referred for but did not receive vertebroplasties before and after the recently published placebo-controlled vertebroplasty trials.
1,2 Furthermore, the procedure was endorsed in 2007 by several American neurologic surgical and radiologic societies that deemed it to be a safe and effective treatment of osteoporotic and neoplastic vertebral fractures. 3 Recent blinded placebo-controlled trials have cast doubt on the efficacy of vertebroplasty. 4, 5 Whether these publications have influenced the practice of vertebroplasty remains unknown. The purpose of this study was to determine whether referral patterns and rates of vertebroplasties at the Mayo Clinic have changed since publication of the placebo-controlled trials.
Materials and Methods
The study was approved by our local institutional review board. This retrospective study compared the number of patients who were evaluated for vertebroplasty and those treated with vertebroplasty before the publication of INVEST 6 and the Australian Trial, between January ) performed a chart review of patient and procedure records to evaluate age, sex, number of treated vertebrae, physician referring the patient for vertebroplasty, and the referring department. Both the evaluations leading to vertebroplasty and those not leading to vertebroplasty were grouped into months by evaluation date. A number of previous case series from our institution have been published by using some portions of this same patient data base. 4, 6 However, we have never previously performed a detailed analysis of referral patterns and rates of vertebroplasty.
Statistical Analysis
We compared the mean number of total referrals per month and the mean number of referrals per month by department by using the Student t test. We divided the number of patients treated with vertebroplasty by the total number of those referred for vertebroplasty evaluation, and these ratios were compared pre-and post-INVEST by using the Student t test. The mean number of vertebroplasty referrals per month dropped significantly from 18.9 Ϯ 5.3 (95% CI, 17.7-20.2) before publication of INVEST to 11.3 Ϯ 3.1 (95% CI, 9.1-13.5) referrals per month after publication (P ϭ .0001). Before publication, 67.3 Ϯ 14.0% (95% CI, 64.0%-70.7%) of patients referred for vertebroplasty were offered vertebroplasty, compared with 76.0 Ϯ 14.9% (95% CI, 65.4%-86.6%) after publication (P ϭ .1083).
Results
Referrals were received from Ͼ20 different departments and 420 different referring physicians. The mean number of referrals per month from the Spine Center and PMR and Orthopedics decreased significantly after the publication (Table) . There was no statistically significant difference between the mean number of referrals from the Department of Hematology per month before and after the publication.
Discussion
In the current study, we found that at our single center, the number of patients referred for consideration of vertebroplasty decreased significantly after the publication of INVEST and the Australian Trial, compared with the rate of such referrals during the 5 years preceding publication of that trial. While we have not specifically queried any referring physicians regarding reasons for changing referral patterns, we believe that the relatively sudden drop in the rate of referral reflects a response to the results published in the placebocontrolled trials. Notably, we continue to offer vertebroplasty to a high proportion of referred patients, indicating that our own belief in the efficacy of the procedure outweighs its risks.
The rate of referrals from the Department of Hematology, most for patients with multiple myeloma, did not change after publication of INVEST and the Australian Trial. Because the INVEST trial specifically excluded patients with myeloma, referring hematologists may believe that the results of the trial do not apply to these types of patients.
Numerous commentaries and editorials have questioned the efficacy of spine augmentation in light of the placebocontrolled trials. [7] [8] [9] [10] [11] [12] Even in light of the trials and commentaries, we continue to perform vertebroplasty relatively frequently. Indeed, we noted in the current study a trend toward an increase in the proportion of referred patients who undergo the procedure. This increase in the percentage of referrals leading to vertebroplasty may indicate that physicians are more stringent than previously regarding whom they refer for vertebroplasty.
Conclusions
The number of vertebroplasty referrals has decreased nearly 50% since the publication of INVEST and the Australian Trial, yet we continue to offer the procedure to a high percentage of referred patients. 
